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Abstract 
Substance P (SP) play a central role in nociceptive transmission and it is an agonist of the 
Neurokinin-1 receptor located in the lamina I of the spinal cord. SP is a major proteolytic product 
of the protachykinin-1 primarily synthesized in neurons. Proprotein convertases (PCs) are 
extensively expressed in the central nervous system (CNS) and specifically cleave at C-terminal 
of either a pair of basic amino acids, or a single basic residue. The proteolysis control of 
endogenous protachykinins has a profound impact on pain perception and the role of PCs remain 
unclear. The objective of this study was to decipher the role of PC1 and PC2 in the proteolysis 
surrogate protachykinins (i.e. Tachykinin 20-68 and Tachykinin 58-78) using cellular fractions of 
spinal cords from wild type (WT), PC1-/+ and PC2-/+ animals and mass spectrometry. Full-length 
Tachykinin 20-68 and Tachykinin 58-78 was incubated for 30 minutes in WT, PC1-/+ and PC2-/+ 
mouse spinal cord S9 fractions and specific C-terminal peptide fragments were identified and 
quantified by mass spectrometry. The results clearly demonstrate that both PC1 and PC2 mediate 
the formation of SP and Tachykinin 58-71, an important SP precursor, with over 50% reduction 
of the rate of formation in mutant PC 1 and PC2 mouse S9 spinal cord fractions.  The results 
obtained revealed that PC1 and PC2 are involved in the C-terminal processing of protachykinin 
peptides and suggest a major role in the maturation of the protachykinin-1 protein. 
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Abbreviations 
SP        Substance P  
NKA    Neurokinin A 
NK1  Neurokinin 1 receptor 
CPE      Endopeptidases E  
TAC1    Tachykinin precursor 1  
NPK    Neuropeptide K  
NPγ     Neuropeptide γ  
PCs    Proprotein convertases  
Tach20-68    β-Preprotachykinin20-68  
Tach58-71         β-Tachykinin58-71   
Tach58-70     β-Tachykinin58-70 
TFA     Trifluoroacetic acid  
MS  Mass spectrometry 
MS/MS Tandem mass spectrometry 
HPLC  High performance liquid chromatography 
IDMS    Isotope dilution mass spectrometry  
ESI       Electrospray ion source  
TIC       Total ion chromatogram  
XIC    Extracted ion chromatogram  
PAM    Peptidylglycine monooxygenase  
PHM    Peptidylglycine hydroxylase 
CNS  Central nervous system 
SRM  Selected reaction monitoring 
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Introduction 
The tachykinin peptide family represents one of the most important neuropeptide family studied 
in mammals. Tachykinins are initially synthesized as inactive protein precursors, which require 
various processing enzymatic reactions to generate bioactive peptides. This typically involves 
endoproteolytic cleavage of precursors at the carboxyl side of specific dibasic residues (i.e. RR, 
RK, KR, KK), followed by the removal of basic amino acids by endopeptidases E (CPE) [1]. The 
tachykinin precursor 1 (Tac1) gene encodes the protachykinin-1 protein containing the sequence 
of four tachykinin peptides, including Substance P (SP) and Neurokinin A (NKA) [2]. Besides, 
the Tac1 gene also encodes other tachykinins, including neuropeptide K (NPK) and neuropeptide 
γ (NPγ) [3]. SP is reported to play a critical role in nociceptive transmission in the CNS [4, 5] and 
it is an agonist of the Neurokinin-1 receptor located in the lamina I of the spinal cord [6, 7]. 
Protachykinin-1 is primarily synthesized in neurons, and maturation occurred in large core dense 
vesicles present in primary afferent terminals. More specifically, a significant proportion of 
primary afferent neurons located in the dorsal root ganglia express high levels of SP and it is 
transported to both, the peripheral and central terminals. It is important to note that the expression 
of SP and NK1 correlates with intensity, frequency, and duration of pain [8-10]. 
As already suggested by previous studies [4], the protachykinin-1 protein is cleaved by the action 
of specific proteases into active neuropeptides by post-translational proteolytic processing during 
axonal transport [11]. Although, several enzymes are involved in the metabolism of the 
protachykinin-1 protein and tachykinin peptides, including neutral endopeptidase [12] and 
angiotensin converting enzyme [13], the role of proprotein convertases (PCs) remains unclear. It 
has been widely demonstrated that several neuropeptides are synthesized by the actions of PCs 
and specific endopeptidases [11, 12, 14, 15]. Comprehensive studies demonstrated that PC1 and 
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PC2 recognize motives composed of either a pair of basic amino acids (KR-, RR-, RK- and KK-), 
or a single residue (R or K) [16, 17]. The role of PCs in the protachykinin-1 protein C-terminal 
processing remains to be demonstrated, but the primary sequence of the protein suggests that PC1 
and PC2 could play an important role in the release of SP. Precisely, PC1 and PC2 could be 
important in the synthesis of SP by cleaving at specific sites illustrated in Figure 1. The 
regulation of endogenous SP levels by proteolysis of precursor peptides is very important and can 
help to better understand the cellular and molecular mechanisms of pain. 
Our main hypothesis is that PC1 and PC2 are important proteolytic enzymes involve in the 
processing of protachykinin-1 resulting into SP, an important neuropeptide. Tach20-68 and Tach58-
78 will be used as surrogate peptides to demonstrate specific cleavage sites shown in Figure 1. 
Accordingly, the main objective of this study was to decipher the role of PC1 and PC2 in the 
proteolysis control of Tach20-68 and Tach58-78 levels using cellular fractions of spinal cords from 
wild type (WT), PC1-/+ and PC2-/+ mice. Major metabolite fragments will be identified by high-
resolution mass spectrometry and the quantification of specific fragment peptides (i.e. Tach58-71, 
Tach58-70, SP) will be performed by HPLC-MS/MS.   
Materials and Methods 
Chemicals and reagents 
β-Preprotachykinin20-68 (Tach20-68), β-Tachykinin58-71 (Tach58-71), β-Tachykinin58-70, Substance P 
(SP) and Substance P3-11 (SP3-11) were purchased from Phoenix Pharmaceuticals (Belmont, CA, 
USA). β-Tachykinin58-78 (Tach58-78) and deuterium labeled analogue peptides were synthesized 
(CanPeptide, Inc., Pointe-Claire, QC, Canada). Proteomic grade trypsin, dithiothreitol (DTT), 
iodoacetamide (IAA), hydrochloric acid (HCl), formic acid, water (LC-MS Optima grade), 
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acetonitrile (LC-MS Optima grade), hexane, trifluoroacetic acid (TFA), sodium phosphate 
dibasic and sodium phosphate monobasic were purchased from Fisher Scientific (NJ, USA).  
Sample Preparation 
Spinal cord tissues (n=6 per genotypes) from male wild type (C57BL/6J), male PC1-/+ (product 
#006327) and male PC2-/+ mice (product #002963) were obtained from The Jackson Laboratory 
(Bar Harbor, Maine, USA) and kept frozen at -80 °C until analysis. Heterozygote animals only 
were used since PC1-/- and PC2-/- exhibit many abnormalities and the survival rate after one week 
is extremely low. Animal genotyping was performed for each animal by Jackson Laboratory 
using a standard PCR assay. Only heterozygous and normal animals were selected for this study. 
All mice were 8 weeks old at time of tissues collection. The animals from all groups (WT, PC1-/+ 
and PC2-/+) were euthanized with an overdose of isoflurane followed by a transection of the 
cervical spine. A flush of saline was performed within the spinal canal to collect the spinal cord 
lumbar enlargement. Tissue samples were snap-frozen in cold hexane (60 °C) and stored 
immediately at -80 °C pending analyses. The study protocol was approved by the Institutional 
Animal Care and Use Committee of the Faculty of Veterinary Medicine of the University of 
Montreal and it was performed in accordance with the guidelines of the Canadian Council on 
Animal Care. 
For each animal group, three spinal cords were pooled and homogenized in a 0.1 M phosphate 
buffer, pH 7.4 at a ratio of 1:5 (w:v). Samples were sonicated 20 minutes and the homogenates 
were centrifuged at 9,000 g for 20 minutes. The total amount of protein in each supernatant was 
determined using the standard Coomassie protein assay (Bradford). This procedure was necessary 
in order to assure the same amount of protein was used for each experiments. Supernatant 
aliquots, designated as S9 fractions, were kept à -80 °C until usage.  
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Metabolism study  
The incubations were performed minimally in triplicate. The incubations were performed in a 
microcentrifuge tube and contained 2 nmol/mL of Tach20-68 or Tach58-78, 0.25 mg/mL of S9 
fraction proteins diluted in 0.1 M phosphate buffer, pH 7.4. Spinal cord S9 enzyme suspensions 
(total volume of 1 mL) were preincubated with 1mM CaCl2 in 0.1 M phosphate buffer (pH 7.4) at 
37°C for 5 min prior fortification with Tach20-68 or Tach58-78. Immediately after fortification of 
the full-length peptide into the spinal cord S9 fraction suspension containing 1mM CaCl2, the 
sampling point for t=0 was taken, and the reaction was quenched after 30 minutes incubation. 
One hundred microliters of samples were taken and mixed with 100 µL of an aqueous solution 
containing 1% TFA to stop the reaction. Samples were centrifuged at 12 000 g for 10 min and 
150 µL of the supernatant was transferred into an injection vial and spiked with 150 µL of the 
deuterated internal standard solution (50 pmol/mL labeled peptides in 0.1% TFA) for mass 
spectrometry analysis. The rate of formation (vi) was calculated based on the concentration of 
each metabolite measured after 30 minutes incubation of the full-length peptides using Equation 
1. 
𝑣" = $[&]$( = [)*)("$*	  ,-./0*1(2]34	  0"1   (1) 
Instrumentation 
The HPLC-MS/MS system included a Thermo Accela autosampler, a Thermo Accela pump and a 
Thermo LTQ-XL Linear Ion Trap Mass Spectrometer (San Jose, CA, USA). Linear ion trap 
instruments typically have unit mass resolution throughout the mass range. The instrument was 
calibrated and the resolution was set at 0.5-0.7 Da at full width at half maximum (FWHM). 
Further analyses were performed using a Thermo Scientific Q-Exactive Orbitrap Mass 
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Spectrometer (San Jose, CA, USA) interfaced with a Thermo Scientific UltiMate 3000 Rapid 
Separation UHPLC system using a pneumatic assisted heated electrospray ion source.  
Data were acquired and analyzed with Xcalibur (San Jose, CA, USA), and regression analyses 
were performed with PRISM (version 6.0f) GraphPad software (La Jolla, CA, USA) using 
nonlinear curve-fitting module with an estimation of the goodness of fit. The calibration lines 
were constructed from the peak-area ratios of targeted neuropeptides and corresponding 
deuterated labeled peptides used as internal standards.  
 
Peptide fragments identification 
The identification of Tach20-68 and Tach58-78 C-terminal processing fragments were performed 
using a hybrid Quadrupole-Orbitrap MS instrument (i.e. Q-Exactive Orbitrap Mass Spectrometer). 
MS detection was performed in positive ion mode and operating in scan mode at high-resolution, 
and accurate-mass (HRAM). Nitrogen was used for sheath and auxiliary gases and they were set 
at 10 and 5 arbitrary units. The heated ESI probe was set to 4000 V and the ion transfer tube 
temperature was set to 300°C. The scan range was set to m/z 200-2000. Data was acquired at a 
resolving power of 140,000 (FWHM), resulting to a scanning rate of ≈ 700 msec/scan when using 
automatic gain control target of 3.0x106 and maximum ion injection time of 200 msec. Product 
ion spectra were acquired a resolving power of 17,500 (FWHM), using automatic gain control 
target of 1.0x106 and maximum ion injection time of 100 msec. The collision energy set to 25 and 
the isolation window was set to 1.5 Da. Instrument calibration was performed prior all analysis 
and mass accuracy was notably below 1 ppm using Thermo Pierce calibration solution and 
automated instrument protocol. All possible C-terminal processing metabolites were simulated in 
silico using mMass [25] to generate survey accurate masses.   
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Protein extraction from S9 fraction and PC1/PC2 MS analysis 
Fifty µL (i.e. precise volume varied to obtain exactly 0.5 mg of proteins) of the S9 suspension 
was transferred to a microcentrifuge tube. The proteins were denatured by heating at 120˚C for 
10 min using heated reaction block. The solution was allowed to cool down 15 minutes and 
proteins were reduced with 20 mM DTT and the reaction was performed at 60 ˚C for 60 minutes. 
Then proteins were alkylated with 40mM IAA and the reaction was performed at room 
temperature for 30 min. Two µg of proteomic-grade trypsin was added and the reaction was 
performed at 40˚C for 24h. The protein digestion was quenched by adding 50 µL of a 1% TFA 
solution. Samples were centrifuged at 12,000 g for 10 min and 75 µL of the supernatants were 
transferred into injection vials for analysis. The HPLC system was a Thermo Scientific UltiMate 
3000 Rapid Separation UHPLC system. The chromatography was achieved using a gradient 
mobile phase along with a microbore column Thermo Biobasic C8 100 × 1 mm, with a particle 
size of 5 µm. The initial mobile phase condition consisted of acetonitrile and water (both fortified 
with 0.1% of formic acid) at a ratio of 5:95. From 0 to 2 minute, the ratio was maintained at 5:95. 
From 2 to 92 minute, a linear gradient was applied up to a ratio of 50:50 and maintained for 2 
minutes. The mobile phase composition ratio was reverted at the initial conditions and the 
column was allowed to re-equilibrate for 15 minutes. The flow rate was fixed at 75 µL/min and 2 
µL of sample were injected. A Thermo Scientific Q-Exactive Orbitrap Mass Spectrometer was 
interfaced with a Thermo Scientific UltiMate 3000 Rapid Separation UHPLC system using a 
pneumatic assisted heated electrospray ion source. MS detection was performed in positive ion 
mode and operating in scan mode at high-resolution, and accurate-mass (HRAM). Nitrogen was 
used for sheath and auxiliary gases and they were set at 10 and 5 arbitrary units. The heated ESI 
probe was set to 4000 V and the ion transfer tube temperature was set to 300°C. The scan range 
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was set to m/z 500-1200. Data was acquired at a resolving power of 140,000 (FWHM), resulting 
to a scanning rate of ≈ 700 msec/scan when using automatic gain control target of 3.0x106 and 
maximum ion injection time of 200 msec. Product ion spectra were acquired a resolving power of 
17,500 (FWHM), using automatic gain control target of 1.0x106 and maximum ion injection time 
of 100 msec. The collision energy set to 25 and the isolation window was set to 1.5 Da. 
Instrument calibration was performed prior all analysis and mass accuracy was notably below 1 
ppm using Thermo Pierce calibration solution and automated instrument protocol. All analysis 
were performed in triplicate. PC1 (P63239) and PC2 (P21661) protein sequences were obtained 
from the The Universal Protein Resource (UniProt) databases. In silico protein digestions, 
peptide mass fingerprinting and MS/MS fragment ion fragmentation were performed using 
mMass [25]. Data analyses were performed using Thermo Scientific SIEVE (ver 2.1) and 
PINPOINT (ver 1.4) software (San Jose, CA, USA). The quantification of PC1 and PC2 in S9 
fraction was performed at the MS level using a label-free approach and specific tryptic peptides 
[26].  
Bioanalytical methods 
The chromatography was achieved using a gradient mobile phase along with a microbore column 
Thermo Biobasic C8 100 × 1 mm, with a particle size of 5 µm. The initial mobile phase condition 
consisted of acetonitrile and water (both fortified with 0.1% of formic acid) at a ratio of 5:95. 
From 0 to 1 min, the ratio was maintained at 5:95. From 1 to 12 min, a linear gradient was 
applied up to a ratio of 45:55 and maintained for 3 min. The mobile phase composition ratio was 
reverted at the initial conditions and the column was allowed to re-equilibrate for 15 min for a 
total run time of 32 min. The flow rate was fixed at 75 µL/min and 2 µL of sample were injected 
using full loop mode. All targeted neuropeptides and deuterium labeled peptides eluted between 
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6.2 to 9.3 min. The mass spectrometer was coupled with the HPLC system using a pneumatically 
assisted electrospray ion source (ESI). The sheath gas was set to 25 units and the ESI electrode 
was set to 4000 V in positive mode. The capillary temperature was set at 300°C and the ion 
transfer tube voltage to 46 V. All scan events were acquired with a 100 ms maximum injection 
time. An activation q = 0.25 and activation time of 30 ms were used for all targeted peptides. The 
mass spectrometer operated for quantitative analyses in full scan MS/MS and the quantification 
was based on specific post-processing SRM extracted ion chromatograms. Specific analysis 
details are presented in Table 1. A specific production ion was used to generate post acquisition 
SRM extracted ion chromatograms for quantification purposes. The method used an isotope 
dilution mass spectrometry (IDMS) strategy for the quantification of the targeted peptides. The 
peptide concentrations were determined using the peak area ratio of the light and heavy analog 
peptide. Tach20-68 and Tach58-78 quantification was performed using d5-SP as an internal standard 
and a calibration curve was constructed using Tach20-68 and Tach58-78 standards. The labeled 
peptides were used at a constant concentration of 50 pmol/mL.  
 
Statistical analysis 
All data were analyzed using a one-way ANOVA followed by Dunnett multiple comparison test. 
Significance was set a priori to p < 0.05. The statistical analyses were performed using PRISM 
(version 6.0f). 
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Results and Discussion 
Analysis of PC1 and PC2 in mouse spinal cord S9 fractions  
Peptide mass fingerprinting (PMF) is an analytical strategy used to identify and quantify proteins 
by assigning specific proteolytic fragment masses with in silico peptide masses generated using 
protein databases and specific digestion algorithms. The method involves that intact proteins are 
cleaved with a proteolytic enzyme (e.g. trypsin) to generate specific and predictable peptides. 
This method relies on the premise that every unique protein will have a distinctive set of peptides, 
consequently unique peptide masses can be found. Moreover, the PMF workflow is 
complemented by matching of MS/MS data for additional peptide sequence characterization. One 
important objective was to quantify PC1 and PC2 in WT, PC1-/+ and PC2-/+ mouse spinal cord S9 
fractions using high-resolution MS. The analytical strategy proposed in this is based on a targeted 
PMF method that specifically relies on upstream identification of specific PC1 and PC2 
proteolytic peptides using in silico digestion to generate a mass list. To avoid false identification, 
only doubly and triply charges ions were survey. The protein analyses were performed using a 
hybrid Quadrupole-Orbitrap mass spectrometer operating in MS at a resolution of 140,000 
(FWHM) and in MS/MS at a resolution of 17,500 (FWHM). Several PC1 and PC2 tryptic 
peptides were identified but the observed abundances were generally low. However, two specific 
proteolytic peptides for PC1 and PC2 were observed within 1 ppm of the exact mass. Specific 
XIC's (exact mass ± 5 ppm)  of each targeted proteotypic peptides was used to perform label-free 
relative quantification based on observed ion abundance. As shown in Figure 2, PC1 and PC2 are 
significantly down-regulated in PC1-/+ and PC2-/+ mouse spinal cord S9 fractions respectively. 
Additionally, theses peptides were analyzed by MS/MS and spectra were dominated by y-type 
fragment ions with low abundance b ions, based on the Roepstorff and Fohlman nomenclature 
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[18]. All collected MS/MS spectra were coherent with the amino acid sequence of each tryptic 
peptide. 
High-resolution mass spectrometry analysis 
Tach20-68 and Tach58-78 were used as surrogate peptides to foster a better understanding of the 
degradation of the protachykinin-1 protein containing the sequence of four tachykinin peptides, 
including SP. Degradation pathways of Tach20-68 and Tach58-78 were determined by incubating 
mouse spinal cord S9 fractions with full-length Tach20-68 and Tach58-78 for 30 min and then 
analyzed the quenched reactions using a hybrid Quadrupole-Orbitrap mass spectrometer 
operating in full-scan mode at high-resolution (i.e. 140 000 FWHM), and accurate-mass (HRAM). 
The total ion chromatogram (TIC) following experiments with Tach20-68 and specific extracted 
ion chromatogram (XIC) shown in Figure 3 reveal that many expected peptide fragments were 
observed. Moreover, as illustrated in Table 2, mass accuracy observed were between -1.6 to 1.5 
ppm for all detected peptide fragments. Interestingly, data clearly demonstrate that SP and SP 
metabolites are generated from full-length Tach20-68 in mouse spinal cord S9 fractions. 
Specifically, SP, SP8-11 and SP1-7 were the most abundant peptide fragments observed. As 
suggested in Figure 1, C-terminal processing of Tach20-68 by PC1 or PC2 can lead to the 
formation of SP.  
Figure 4 shows the total ion chromatogram (TIC) following experiments with Tach58-78 and 
specific extracted ion chromatogram (XIC). Again, many expected peptide fragments were 
observed, particularly C-terminal fragments.  A list of the most abundant peptide fragments was 
shown in Table 2. The observed mass accuracy observed was between -1.2 - 2.2 ppm for all 
detected peptide fragments. C-terminal processing of Tach58-78 in mouse spinal cord S9 fractions 
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lead to the formation of Tach58-71, an important precursor of SP. It is well know that Tach58-71 will 
be cleave by endopeptidases E (CPE) and form Tach58-70 and Tach58-69 and then process by 
peptidylglycine monooxygenase (PAM) or peptidylglycine hydroxylase (PHM) to form SP. 
These results are very interesting since as suggested in Figure 1, C-terminal processing of Tach58-
78 by PC1 or PC2 can lead to the formation of Tach58-71 a precursor of SP. Please note that all 
MS/MS spectra acquired in high-resolution were compatible with the amino acid sequence of the 
peptide fragments.  
Quantitative analysis and Isotopic Dilution Method 
Full-scan and product ion mass spectra for all peptides and internal standards were obtained in 
positive ion mode. The full-scan electrospray mass spectrum of targeted peptides displayed the 
formation of characteristic pseudo molecular ions [M+nH]n+ and the fragment ions observed in 
MS/MS spectra were annotated based on the Roepstorff and Fohlman nomenclature [18]. Details 
on MS parameters and SRM transitions are reported in Table 3. Full-scan and product ion mass 
spectra are necessary to identify and characterize each neuropeptide. The full-scan electrospray 
mass spectra of targeted neuropeptides showed a base peak pseudo molecular ions at m/z 994.6 
(6+) for Tach20-68, 602.5 (+4) for Tach58-78, 564.0 (+3) for Tach58-71, 512.0 (+3) for Tach58-70 and 
674.5 (+2) for SP. Corresponding labeled peptides show compatible pseudo molecular ion 
profiles. All precursor ion masses are listed for each unlabeled and labeled peptide in Table 3. 
Figure 4 presents product ion spectra (MS/MS) for targeted tachykinin peptides obtained and 
typical b and y positive ion fragments were observed. The observed collision-induced 
dissociation spectra were all compatible with the peptide sequences. Additionally, we selected 
and optimized the most abundant and specific product ion for each peptide to generate post 
acquisition SRM extracted ion chromatograms in order to achieve the best sensitivity, selectivity 
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and reproducibility. Furthermore, selected SRM transitions were monitored for mouse spinal cord 
S9 fractions and compared with reference materials. The overlay SRM extracted ion 
chromatograms display in Figure 5 demonstrate a suitable concordance between peptide 
reference standards and peptides observed in spinal cord S9 fractions following the degradation 
of full-length tachykinin peptides. Due to the important dilution factor of spinal cord S9 fraction 
used during this study, the endogenous levels were below the limit of quantification. The heavy-
label versions of Tach58-71, Tach58-70 and SP were spiked in spinal cord S9 fractions to quantify 
specific N-terminal and C-Terminal Tach20-68 and Tach58-78 metabolite fragments.  After 
optimization, the concentration of spiked labeled peptides, it was determined that a final 
concentration of 50 pmol/mL would lead to adequate measurements of each targeted peptide 
using SRM transitions. All labeled peptides are clearly distinguishable from unlabeled version by 
mass spectrometry, and the ratio of the unlabeled peptides to stable isotope-labeled peptides 
found in mouse spinal cord S9 fraction supernatants can be used to calculate the absolute 
concentration of each peptide monitored. The linearity response was tested at concentration 
raging from 1 to 500 pmol/mL for each targeted peptide. Correlation assessments between 
measured peak area ratios and nominal concentrations were performed and results show excellent 
correlations (R2 = 0.9935 to 0.9986). The precision and accuracy results are shown in Table 4 for 
all targeted tachykinin peptides. Accordingly, the analytical method provided adequate figures of 
merit for targeted peptide analysis performed during this study. 
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Metabolic stability of Tach20-68 and Tach58-78 in mouse spinal cord S9 fractions 
Tachykinins concentration in mouse spinal cord is regulated by proteolysis generating a series of 
peptide metabolites. Tissue S9 fractions are commonly used to study metabolism since this 
fraction contains the cytosol and microsomes [19, 20]. To determine the pathways for Tach20-68 
and Tach58-78 degradation in mouse spinal cord S9 fractions, we incubated spinal cord S9 
fractions with full-length Tach20-68 and Tach58-78 for 30 min and then analyzed the quenched 
reactions by HPLC-MS/MS to determine the metabolic stability and identify specific N-terminal 
and C-terminal fragments produced. The Figure 6 revealed that proteolysis of Tach20-68 and 
Tach58-78 is occurring in mouse spinal cord S9 fractions. The results show that > 87% of the full-
length peptides degraded in 30 minutes. Furthermore, negative control (i.e. no S9 proteins) shows 
no degradation after a 30 minutes incubation period for both full-length peptides. Results 
presented in Figure 3, 4 and 6 revealed significant Tach20-68 and Tach58-78 degrading activity in 
mouse spinal cord S9 fractions. 
Contribution of PC1 and PC2 in Tach20-68 C-terminal processing  
Neuropeptides are synthesized as larger precursors that undergo endoproteolysis at specific sites. 
Several neuropeptide-processing enzymes were identified in mammalian cells [1, 21, 22]. 
Proprotein convertase family including PC1 and PC2 are known to be present in numerous 
neuroendocrine cells. Specifically, PC1 and PC2 cleaved at the C-terminal side of paired or 
single basic residue within proneuropeptides [11]. Proteines convertases processing yields 
neuropeptide intermediates with C-terminal basic residues (R or K) that are removed by 
carboxypeptidase E [23].  As suggested in Figure 2, we believed that PC1 or PC2 could cleave 
Tach20-68 in between R57R58 to form SP. Full-length Tach20-68 was incubated for 30 minutes in 
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WT, PC1-/+ and PC2-/+ mouse spinal cord S9 fractions and metabolites quantified by HPLC-
MS/MS. The rate of formation (vi) was determined using Equation 1. Interestingly, as shown in 
Figure 7A, Tach20-68 cleavage between R57R58 to form SP occurred and the rate of formation (vi) 
is significantly impeded in PC1-/+ and PC2-/+ mouse spinal cord S9 fractions. Cleavage after the 
pair basic amino acid was not observed (R57R58P59) since the arginine (R) residue at position 58 is 
followed by a proline (P). These results clearly demonstrate that PCs regulate SP concentration 
through C-terminal processing of protachykinin-1 protein and related propeptides. 
Contribution of PC1 and PC2 in Tach58-78 C-terminal processing  
Full-length Tach58-78 was incubated for 30 minutes in WT, PC1-/+ and PC2-/+ mouse spinal cord 
S9 fractions and specific C-terminal peptide fragments were quantified by HPLC-MS/MS. The 
rate of formation (vi) was determined using Equation 1. Figure 7B distinctly demonstrate that 
PC1 and PC2 are involved in the proteolysis of Tach58-78 in the spinal cord. The results 
demonstrate that PC2 mediate the processing of Tach58-78 to Tach58-71 cleaving immediately after 
a pair of basic amino acids (i.e. K70R71D72).  Despite not being statistically significant, the rate of 
formation of Tach58-71 in PC1-/+ mouse spinal cord S9 fractions was reduced. Furthermore, the 
rate of formation (vi) of downstream metabolites, including Tach58-70 and SP was significantly 
hampered in both, PC1-/+ and PC2-/+ mouse spinal cord S9 fractions. We believe these results 
shown the importance of PC1 and PC2 in the C-terminal processing of protachykinin-1 protein 
and related propeptides in the regulation of SP concentration in the spinal cord.  
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Conclusion 
The results obtained revealed that PC1 and PC2 are involved in the C-terminal processing of 
protachykinin peptides and suggest a major role in the maturation of the protachykinin-1 protein. 
As already presented, the protachykinin-1 protein is cleaved by the action of specific proteases 
into active neuropeptides during axonal transport. Interestingly, depolarization of a neuron 
containing proneuropeptides stimulates proprotein convertases processing [24]. As a consequence, 
the stimulation of proprotein convertases processing will result in the liberation of higher 
concentration of SP into the intersynaptic space since both PC1 and PC2 are involved in the C-
terminal processing of protachykinin peptides. Thus PCs could be a drug targets with the premise 
of partially inhibiting the release of SP. However, further study is needed since partial inhibition 
of PC1 or PC2 may also impact the endogenous opioid system.    
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Table 1. Principal peptide fragments observed following the incubation of Tach20-68 in mouse 
spinal cord S9 fractions 
Peptide Sequence Charge 
state (z) 
Theoretical 
mass 
Observed 
Mass 
Relative 
Error (ppm) 
Tach20-68 EEIGANDDLNYWSDWYDSDQIKEELP
EPFEHLLQRIARRPKPQQFFGLM(NH2) 
6 994.6548 
 
994.6536 -1.21 
Tach31-68 WSDWYDSDQIKEELPEPFEHLLQRIA
RRPKPQQFFGLM(NH2 
5 946.6813 
 
946.6798 
 
-1.58 
Tach35-68 YDSDQIKEELPEPFEHLLQRIARRPKP
QQFFGLM(NH2) 
5 831.8378 831.8368 
 
-1.20 
SP RPKPQQFFGLM(NH2) 2 674.3716 674.3713 0.45 
SP3-11 KPQQFFGLM(NH2) 2 547.7944 547.7951 1.28 
SP8-11 FGLM(NH2) 1 466.2483 466.2490 1.50 
SP1-7 RPKPQQF 2 450.7561 450.7566 1.11 
Tach1-11 EEIGANDDLNY 2 626.7700 626.7705 0.80 
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Table 2. Principal peptide fragments observed following the incubation of Tach58-78 in mouse 
spinal cord S9 fractions 
Peptide Sequence Charge 
state (z) 
Theoretical 
mass 
Observed 
Mass 
Relative 
Error (ppm) 
Tach58-78 RPKPQQFFGLMGKRDADSSIE 4 602.5595 
 
602.5601 -1.00 
Tach58-71 RPKPQQFFGLMGKR 3 563.9838 
 
563.9841 
 
0.53 
Tach58-70 RPKPQQFFGLMGK 3 511.9501 511.9507 
 
1.17 
Tach58-69 RPKPQQFFGLMG 2 703.3741 703.3740 -0.14 
SP RPKPQQFFGLM(COOH) 2 674.8634 674.8637 0.45 
SP1-9 RPKPQQFFGL 2 552.8011 552.8020 1.63 
SP1-7 RPKPQQF 2 450.7561 450.7571 2.22 
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Table 3. Summary of peptide quantification parameters used for HPLC-MS/MS analysis and post 
processing SRM 
 
Peptide Precursor 
ion (m/z) 
Charge state 
(z) 
Product ion Fragment 
ion 
Collision 
Energy 
Tach20-68 994.6 6 1137.0 y37 4+ 35 
Tach58-78 602.5 4 716.4 b19 3+ 35 
Tach58-71 
d5-Tach58-71  
564.0 
565.7 
3 661.1 
666.1 
y6 33 
Tach58-70 
d5-Tach58-70 
512.0 
513.7 
3 652.4 
657.4 
y6 33 
SP 
d5-SP 
674.5 
677.0 
2 600.3 
602.8 
b102+ 32 
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Table 4. Summary of peptide quantification figure of merits obtain in fortified S9 fractions 
Peptides Spinal cords S9 fractions  
 Accuracy (%NOM) Precision (%CV) R2 
    
Tach20-68 95.2 - 110.3 3.2 - 10.7 ≥ 0.9954 
Tach58-78 94-5 - 105.6 1.8 - 6.8 ≥ 0.9935 
Tach58-71 96.4 - 100.9 1.5 - 11.3 ≥ 0.9986 
Tach58-70 95.2 - 100.7 1.1 - 12.2 ≥ 0.9954 
SP 97.4 - 102.7 0.6 - 4.6 ≥ 0.9985 
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Figure Legends 
Figure 1. Protachykinin-1 processing by proprotein convertases (PC1 and PC2). Tachykinins 
have several paired and single basic amino acid cleavage sites and based on the sequence, various 
processing intermediates can be derived leading to SP and Tach58-71.  
Figure 2. Determination of the relative abundance of PC1 and PC2 in mouse spinal cord S9 
fractions using a bottom-up proteomic based analytical strategy. (A) Two specific PC1 tryptic 
peptides were identified and peak abundance (m/z 903.0196 ± 5 ppm; m/z 959.0333 ± 5 ppm) 
were significantly down-regulated in PC1-/+ but remain unchanged in PC2-/+. (B) Also, two 
specific PC2 tryptic peptides were identified and peak abundance (m/z 922.9860 ± 5 ppm; m/z 
867.8883 ± 5 ppm) were significantly down-regulated in PC2-/+ but remain unchanged in PC1-/+.  
Figure 3. Total Ion Chromatograms (TIC) and specific Extracted-ion chromatograms (XIC) for 
targeted tachykinin peptides following the incubation of Tach20-68 in mouse spinal cord S9 
fractions. XIC's were generated using the theoretical mass value with a ± 5 ppm extraction 
window. Overley XIC's of time 0 (black) and time 30 min (red) reveal the apparition of specific 
peptide fragments.  
Figure 4. Total Ion Chromatograms (TIC) and specific Extracted-ion chromatograms (XIC) for 
targeted tachykinin peptides following the incubation of Tach58-78 in mouse spinal cord S9 
fractions. XIC's were generated using the theoretical mass value with a ± 5 ppm extraction 
window. Overley XIC's of time 0 (black) and time 30 min (red) reveal the apparition of specific 
peptide fragments.  
Figure 5. Product ion spectra (MS2) of Tach20-68, Tach58-78, Tach58-71, Tach58-70 and SP. Overlay 
SRM extracted ion chromatograms of a reference (black) and S9 spinal cord tissue (red). 
Figure 6. Evaluation of the metabolic stability of Tach20-68 and Tach58-78 in mouse spinal cord S9 
fractions. The degradation of full-length peptides occurred only with the presence of S9 proteins 
and demonstrates that Tach20-68 and Tach58-78 undergoes proteolytic processing in mouse spinal 
cord S9 fractions. 
Figure 7. Assessments of PC1 and PC2 involvement in the proteolysis of Tach20-68 (A) and 
Tach58-78 (B). Results suggest that PC1 and PC2 are involved in the proteolytic processing of 
Tach20-68 and Tach58-78 leading to the formation of SP and Tach58-71 respectively. 
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